Envista (NVST) Stock Price, News & Analysis

Company Overview

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Key Stats

• Today's Range: $19.94 to $20.34
• 50-Day Range: $18.09 to $20.81
• 52-Week Range: $14.22 to $23.00
• Volume: 1.70 million shs
• Average Volume: 2.69 million shs
• Market Capitalization: $3.37 billion
• P/E Ratio: 63.33
• Dividend Yield: N/A
• Price Target: $20.92
• Consensus Rating: Hold

Envista Stock Analysis - MarketRank™

Envista scored higher than 70% of companies evaluated by MarketBeat, and ranked 290th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Envista has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Envista has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 21.00%

Earnings Growth

Earnings for Envista are expected to grow by 21.00% in the coming year, from $1.00 to $1.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Envista is 63.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Envista is 63.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.01.

Price to Earnings Growth Ratio

Envista has a PEG Ratio of 1.08. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Envista has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.61% of the outstanding shares of Envista have been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Envista has recently decreased by 0.36%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Envista does not currently pay a dividend.

Dividend Growth

Envista does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

6.61% of the outstanding shares of Envista have been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Envista has recently decreased by 0.36%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Envista has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Envista this week, compared to 7 articles on an average week.

Search Interest

8 people have searched for NVST on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Envista to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Envista insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Envista is held by insiders.

NVST Stock Analysis - Frequently Asked Questions

How have NVST shares performed this year?

Envista's stock was trading at $19.29 at the beginning of the year. Since then, NVST shares have increased by 5.1% and is now trading at $20.2650.

How were Envista's earnings last quarter?

Envista Holdings Corporation (NYSE:NVST) posted its quarterly earnings results on Thursday, July, 31st. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. Envista's revenue for the quarter was up 7.7% compared to the same quarter last year.
Read the conference call transcript.

When did Envista IPO?

Envista (NVST) raised $603 million in an initial public offering on Wednesday, September 18th 2019. The company issued 26,800,000 shares at $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley acted as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Who are Envista's major shareholders?

Top institutional shareholders of Envista include Geode Capital Management LLC (1.76%), Pzena Investment Management LLC (1.45%), Brickwood Asset Management LLP (1.21%) and Tweedy Browne Co LLC (0.86%). Insiders that own company stock include Amir Aghdaei, Eric Conley, Howard H Yu, Mark E Nance, Eric D Hammes and Stephen Keller.
View institutional ownership trends.

How do I buy shares of Envista?

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Envista own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Envista investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVST
• CIK: 1757073
• Web: www.envistaco.com
• Phone: 714-817-7000
• Fax: 714-817-5450
• Employees: 12,300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Envista: $20.92
• High Price Target: $25.00
• Low Price Target: $17.00
• Potential Upside/Downside: +3.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.32
• Trailing P/E Ratio: 63.33
• Forward P/E Ratio: 20.27
• P/E Growth: 1.08
• Net Income: -$1.12 billion
• Net Margins: 2.11%
• Pretax Margin: 4.54%
• Return on Equity: 4.84%
• Return on Assets: 2.68%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 2.44
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: $2.51 billion
• Price / Sales: 1.34
• Cash Flow: $1.66 per share
• Price / Cash Flow: 12.18
• Book Value: $18.89 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 166,180,000
• Free Float: 164,022,000
• Market Cap: $3.37 billion
• Optionable: Optionable
• Beta: 1.00